Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05703958 · ClinicalTrials.gov registry record
Exactech Proximal Humerus Fracture Plate System Post Market Clinical Follow-up
A clinical trial of Proximal Humeral Fracture and Fracture Dislocation, sponsored by Exactech.
- Recruiting
- Registry status
- 151
- Enrollment target
- 1
- Study location
NCT05703958: Recruiting study of Proximal Humeral Fracture and Fracture Dislocation, sponsored by Exactech.
NCT05703958 is a study of Proximal Humeral Fracture and Fracture Dislocation that is actively recruiting participants, run by Exactech. The registered enrollment target is 151 participants, above the 108-participant average among 3 other Proximal Humeral Fracture trials with a reported enrollment target (40% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05703958, a study of Proximal Humeral Fracture and Fracture Dislocation, is actively recruiting participants, sponsored by Exactech.
- RECRUITING
- Registry status
- 151 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to collect and evaluate long-term clinical outcomes data in order to better understand the safety and performance of the Equinoxe Proximal Humerus Fracture Plates over time. This study will follow subjects for a period of up to 10 years post-surgery.
Primary Outcome
Shoulder Arthroplasty Smart (SAS) score - 6 questions based on 3 objective active range of motion and 3 subjective measures of pain and function. Score range of 0 to 100 where 100 indicates the best score
Conditions Studied
Study Locations (1)
New York
- NYU Grossman School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2034-09-30 |
What NCT05703958 shows while recruiting
NCT05703958 is an observational study that tracks outcomes without assigning an intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, above the 108-participant average among 3 other Proximal Humeral Fracture trials with a reported enrollment target (40% higher).
The record links to 3 conditions, with Proximal Humeral Fracture appearing as the primary indexed condition, and to 0 interventions.
NCT05703958 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05703958 about?
NCT05703958 is a clinical study titled "Exactech Proximal Humerus Fracture Plate System Post Market Clinical Follow-up". The objective of this study is to collect and evaluate long-term clinical outcomes data in order to better understand the safety and performance of the Equinoxe Proximal Humerus Fracture Plates over time. This study will follow subjects for a period of up to 10 years post-surgery.
What is the current status of trial NCT05703958?
This trial is currently recruiting. The enrollment target is 151 participants. The study started on 2023-04-19. Estimated completion is 2034-09-30.
What conditions does trial NCT05703958 study?
This clinical trial studies the following conditions: Proximal Humeral Fracture, Fracture Dislocation, Non-Union Fracture.
Who is sponsoring clinical trial NCT05703958?
This trial is sponsored by Exactech, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05703958 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proximal Humeral Fracture
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI